Biofourmis completed the acquisition of Gaido Health from Takeda.

Biofourmis, which designs and develops health analytics platform based on human physiology, completed the acquisition of Gaido Health, a Los Angeles-area based digital therapeutics company focused on the oncology market, from Takeda, a Japanese multinational pharmaceutical and biopharmaceutical company. Financial terms were not disclosed. "Biofourmis' digital therapeutics solution for oncology—now bolstered with this acquisition of Gaido Health—is based on an innovative approach that continuously monitors patients' physiology biomarkers and symptoms, detects early signs of complications, and arms care teams with tools to intervene early to prevent medical crises, improve outcomes and lower costs. The platform also empowers patients with cancer to self-manage symptoms using Biofourmis' artificial intelligence [AI]-based Biovitals® treatment algorithms, which improves engagement and quality of life," Kuldeep Singh Rajput, Biofourmis CEO.